Catalyst
Slingshot members are tracking this event:
Ionis Pharma (IONS) to complete Phase 2 study of ISIS-GCGRRx in Patients With Type 2 Diabetes before 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IONS |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 04, 2017
Occurred Source:
http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2233755
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Type 2 Diabetes, Phase 2 Study, Isis-gcgrrx, Isis 449884
